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Role of iron in postlschemic renal injury in the rat. To determine
whether iron participates in free radical-mediated postischemic renal
injury and lipid peroxidation, we examined the effects of removal of
endogenous iron or provision of exogenous iron following renal ische-
mia, as well as the effects of renal ischemia and reperfusion on renal
venous and urinary 'free" iron. Rats underwent 60 minutes of renal
ischemia and were studied after either 24 hours (inulin clearance) or 15
minutes (renal malondialdehyde content) of reperfusion. Infusion of the
iron chelator deferoxamine (200 mg/kg/hr) during the first 60 minutes of
reperfusion resulted in a marked improvement in renal function (inulin
clearance: 879 154 vs. 314 74 d/min; P < 0.025) and a reduction in
lipid peroxidation (renal malondialdehyde: 0.449 0.06 vs. 0.698
0.08 mmol/mg prot; P < 0.05) compared to control animals. Infusion of
50 mg/kg/hr deferoxamine also protected renal function after ischemia
(inulin clearance: 624 116 vs. 285 90 d/min; P < 0.05) and resulted
in less histologic injury. Iron-saturated deferoxamine had no protective
effect. Conversely, infusion of the iron complex EDTA-FeCI3 during
reperfusion exacerbated postischcmic renal dysfunction and lipid per-
oxidation. Following renal ischemia there was no detectable increase in
"free" iron in arterial or renal venous plasma. However, urinary
"free" iron increased 10- to 20-fold following reperfusion. Iron chela-
tors which underwent filtration and gained access to this free iron in the
urine (free deferoxamine or inulin-conjugated deferoxamine) provided
protection, whereas a chelator confined to the vascular space (dextran-
conjugated deferoxamine) did not. We propose that during ischemia and
reperfusion iron is released from storage pools and is available to
catalyze hydroxyl radical formation and lipid peroxidation. Adminis-
tration of the iron chelator deferoxamine during reperfusion limits
postisehemic renal dysfunction and free radical-mediated lipid peroxi-
dation. These effects appear to take place in the urinary space or along
the brush border membrane adjacent to the urinary space.
Oxygen free radicals are now well recognized to contribute to
kidney damage after ischemia and reperfusion [1—5]. During
ischemia ATP is dephosphorylated and the adenosine is further
degraded, During reperfusion, When xanthine oxidase converts
hypoxanthine to xanthine, an electron is transferred from
hypoxanthine to molecular oxygen to produce the oxygen free
radical superoxide radical (02). Superoxide radical is further
metabolized to hydrogen peroxide and hydroxyl radical (OH.).
All three reactive oxygen species have toxicity, but hydroxyl
radical is the most highly reactive [1].
The toxicity of reactive oxygen species is a consequence of
their ability to react with proteins, lipids, polysaccharides, and
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DNA [6, 7]. Essential enzymes with sulfhydryl groups can be
inactivated when oxidized. Peroxidation of polyunsaturated
fatty acids makes membranes more permeable and can interfere
with mitochondrial and cellular function. Depolymerization of
polysaccharides also affects cellular function, whereas degra-
dation of DNA could interfere with postischemic repair which
requires cell division.
Some transition metals, in particular iron and copper, cata-
lyze the reaction shown here whereby superoxide radical and
hydrogen peroxide yield hydroxyl radical [6]. This net reaction
is known as the Haber-Weiss reaction. This reaction can be
separated into two steps:
02 + Fe3 — Fe2 + 02
H2O2 + Fe2 — OH. + OH— + Fe3
(1)
(2)
In the first step ferric iron is reduced by superoxide radical. In
the second step iron reduces hydrogen peroxide to hydroxyl
radical (Fenton's reaction). Although iron in tissues is usually
tightly bound to ferritin, xanthine oxidase-derived superoxide
radical can release iron from ferritin [8—101. This free iron can
then participate in the formation of hydroxyl radical. In addition
iron might directly induce lipid peroxidation [11, 12].
The purpose of this study was to determine the role of iron in
postischemic renal injury because of the postulated role of iron
in catalyzing hydroxyl radical formation and lipid peroxidation.
We sought to determine whether removal of endogenous iron
would attenuate renal injury after ischemia and whether provi-
sion of exogenous iron would exacerbate postischemic injury.
We also sought to determine whether there were detectable
changes in free iron in either plasma or urine following ischeniia
and perfusion. Finally, we sought to determine the nephron site
where iron chelators were protective against postischemic
injury.
Methods
Model of ischemic renal failure
Male Sprague-Dawley rats (Harlan, Madison, Wisconsin,
USA) weighing 225 to 275 g were used. They were allowed free
access to food and water until the time of study. Rats were
anesthetized with sodium pentobarbital (60 mg/kg i.p.), and a
femoral vein catheter (PE-50) inserted for administration of
drugs. Bilateral flank incisions were made and the right kidney
was removed. The left kidney was exposed, the perirenal fat
removed, and the left renal artery exposed. Heparin (100 lU/kg,
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i.v.) was administered, and a non-traumatic vascular clamp was
then placed across the renal artery for 60 minutes. After
removal of the clamp the animal was sutured and allowed to
recover for study 24 hours later.
The effects of renal ischemia on renal function were assessed
by measurement of inulin clearance 24 hours after renal ische-
mia. Animals were anesthetized with pentobarbital and placed
on a heated, temperature-controlled table. Catheters were
placed in the femoral artery and vein, and ureter. An infusion of
10% inulin in saline was begun at 0.06 mI/mm for 15 minutes,
followed by 0.02 mi/mm for the duration of the study. After a 60
minute equilibration period, three 20 minute urine collections
were made. Blood for plasma inulin determination was obtained
at the midpoint of each collection. The concentration of inulin
in urine and blood was determined by the anthrone method and
inulin clearance was calculated by the standard formula.
Lipid peroxidation was measured after a 60 minute ischemia
plus 15 minute reperfusion, a time of maximum lipid peroxida-
tion [2, 3] by determining the renal cortical content of the lipid
peroxidation product malondialdehyde (MDA). MDA was mea-
sured by the method of Ohkawa, Ohishi and Yagi [13]. After
ischemia plus reflow, kidneys were rapidly removed and placed
in iced phosphate buffered saline. Sections of renal cortex were
suspended in a total volume of 3 ml 100 mM KC1 plus 0.003 M
EDTA and homogenized with a Polytron (Brinkman Instru-
ments, Wesbury, New York, USA) at setting 8 for 15 seconds.
Homogenates were then centrifuged at 600 g for 10 minutes.
Two hundred microliters of supernate were added to 0.2 ml
8.1% sodium dodecyl sulfate, 1.5 ml 20% acetic acid (pH 3.5),
1.5 ml 0.8% thiobarbituric acid and 6.6 ml water. This solution
was heated to 95°C for 60 minutes. After addition of 1.0 ml
water and 5.0 ml of an n-butanol/pyridine mixture (15:1 vol/vol)
the mixture was vigorously shaken and centrifuged at 2000 g for
15 minutes. The absorbance of the upper organic layer at 532
nm was determined in a spectrophotometer. Absorbance of
tissue samples was compared to results obtained using malon-
aldehyde tetraethylacetal standards (Sigma Chemical Co., St.
Louis, Missouri, USA). MDA values were expressed per mg
protein. All determinations of MDA were performed in dupli-
cate.
Removal of endogenous iron
To remove endogenous iron after ischemia, the iron chelator
deferoxamine (deferoxamine mesylate, Ciba Pharmaceutical
Co., Summit, New Jersey, USA) was infused during the first
hour of reperfusion. In the first set of studies deferoxamine (50
mg/ml in 5% dextrose) was infused at the rate of 200 mg/kg/hr
beginning one minute before removal of the renal artery clamp
and continuing for 60 minutes. Inulin clearance was determined
24 hours later in six rats. Control rats were treated similarly
except that they received an infusion of 5% dextrose of 1 ml/hr.
To ascertain that any beneficial effect of deferoxamine was due
to its ability to chelate iron, an additional group of animals was
infused with iron-saturated deferoxamine. Iron-saturated defer-
oxamine was produced by mixing equimolar amounts of defer-
oxamine and FeC13 and infused to deliver a dose containing an
amount of deferoxamine of 200 mg/kg/hr for the first hour of
reperfusion. The effect of iron-saturated deferoxamine on post-
ischemic renal function was determined by measuring inulin
clearance 24 hours later. In other studies deferoxamine was
given in a dose of 50 mg/kg/hr for one hour and the effect on
inulin clearance determined 24 hours later. In another group of
rats deferoxamine or the dextrose vehicle was given at the same
rate during the first 15 minutes of reperfusion. The animals were
then sacrificed and their kidneys removed for determination of
malondialdehyde content.
The systemic and renal hemodynamic effects of deferox-
amine in normal rats was also determined. Animals were
prepared for inulin clearance studies as described above. In
addition a 23 gauge needle was inserted into the left renal vein
so that samples of renal vein blood could be removed to
determine the renal extraction of inulin and calculate renal
plasma flow. Two 20-minute collections were performed, then
an infusion of deferoxamine was begun in a dose of 200
mg/kg/hr. After 10 minutes two additional clearance periods
were performed.
Effect of iron infusion
To attempt to increase iron availability after ischemia, the
iron complex EDTA-FeC13 was infused during the first five
minutes of reperfusion in a dose of 24 nmollkg [14, 15].
Ferric-EDTA was prepared by mixing equimolar amounts of
Na2H2 EDTA and FeCl3 (12 ILM)in saline [16]. Control animals
received EDTA in saline (0.5 ml) during the first five minutes of
reperfusion. A second control group received 5% dextrose
during the first five minutes of reperfusion.
Morphologic studies
Kidneys from control animals (N = 6) and deferoxamine-
infused animals (N = 6; 50 mg/kglhr) were examined by light
microscopy. After ischemia and 24 hours of reflow, kidneys
were fixed by perfusion at mean arterial pressure with 1.25%
giutaraidehyde in 0.1 M sodium phosphate buffer (pH 7.4,
osmolality 300 mOsmlkg), followed by immersion in fixative for
three hours. Sections were embedded in paraffin and stained
with hematoxylin and eosin. Slides were coded by a technician
not involved in this study, and reviewed in a blinded manner
and scored by one of us (M.S.P.) using a semiquantitative scale
to evaluate the presence and extent of tubular epithelial cell
flattening, brush border loss, cell membrane bleb formation,
cytoplasmic vacuolization, cell necrosis, interstitial edema and
tubular lumen obstruction [2]. For each kidney, 50 cortical
tubules from at least 10 different areas were scored with care
taken to avoid repeated scoring of different convolutions of the
same tubule. Higher scores represent more severe damage
(maximum score per tubule was ten points).
Effect of ischemia and reperfusion on iron availability
Plasma and urine samples were analyzed for "catalytic" iron
using an assay developed by Gutteridge, Rowley and Halliwell
[17, 18]. In this assay trace amounts of free (non-protein bound)
iron capable of participating in superoxide-dependent hydroxyl
radical formation can be detected by measuring the degradation
of DNA by bleomycin, a reaction which requires the presence
of Fe2t
All reagents were prepared in pyrogen-free water treated by
distillation, reverse osmosis, and shaking with Chelex-100
(Biorad Laboratories, Richmond, California, USA) to remove
contaminating iron using new sterile plastic tubes. Bleomycin
sulfate (Bristol-Myers Company) was prepared as a 1 mg/ml
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solution. Calf thymus DNA (Sigma) was also prepared as a 1
mg/ml solution. The reaction mixture contained 125 .tl DNA,
12.5 d bleomycin, 25 j.d MgSO4 (50 mM), 25 d sample, 12.5 1td
HC1 (10 mM), 25 d H20 and 25 l fresh ascorbic acid. After
mixing, the tubes were incubated at 37°C for two hours. To stop
the reaction 250 1td EDTA (100 mM) was added. The content of
each tube was transferred to a 12 x 75 polypropylene tube to
which 250 .d thiobarbuturic acid (1% wt/vol in 50 mi NaOH)
and 250 d HC1 (25% vol/vol) were added. After heating to
100°C for 15 minutes, the tubes were cooled and the absorbance
of the solution measured at 532 nm. A standard curve was
prepared for each assay with FeCI3 dissolved in chelex-treated
pyrogen free water with HC1 (10 mM) added to adjust pH to 7.3.
To determine the effect of renal ischemia on plasma free iron,
carotid artery and renal vein blood samples were obtained
before ischemia, at the end of 60 minutes of ischemia and
following 10, 30, and 60 minutes of reperfusion. Urine was
collected for 30 minute periods before ischemia, between 15 and
45 minutes of reperfusion (urine output in the first 15 mm of
reperfusion was often negligible), and between 45 and 75
minutes of reperfusion.
Nephron site of protection by iron chelators
Studies were undertaken to determine whether the free iron
released into the urinary space was the critical iron pool
responsible for promotion of free radical formation and renal
injury during reperfusion. Following 60 minutes of ischemia one
of three deferoxamine compounds, or an appropriate vehicle,
was infused during the first hour of reperfusion. Inulin clear-
ance was measured 24 hours later, as described above. The
three iron chelating compounds were free deferoxarnine and
deferoxamine conjugated to biocompatible polysaccharides,
either inulin (Sigma) or dextran T-40 (Rheomacrodex, Pharmacia,
Uppsala, Sweden). The latter two compounds were supplied by
Biomedical Frontiers (Minneapolis, Minnesota). Briefly, the
compounds were synthesized by oxidizing the polysaccharide
with periodate, and allowing the resulting dialdehydes to form a
Schiff base with the free amino group of the terminal lysine
amino group of deferoxamine. This Schiff base was initially
reduced with sodium cyanoborohydride, and remaining unre-
duced aldehyde groups were subsequently reduced with sodium
borohydride. Free deferoxamine and reaction products were
removed by extensive dialysis against distilled water. The
soluble conjugates were then lyophilized and stored dessicated
until use. Iron content of the deferoxamine-polysaccharide
conjugates was determined by addition of excess ferrous or
ferric iron to stock solutions. Typically, the weight fraction of
chelator in these conjugates varied from 10 to 30%. The ability
of polysaccharide-bound chelator to bind iron was not altered
following incorporation into the polymer matrix (Hallaway PE,
Eaton JW, Panter SS, Hedlund BE: unpublished data).
Free deferoxamine has a molecular weight of 560 and a very
small effective molecular radius. Following infusion deferox-
amine would have access to the blood stream and would then
appear in the urinary space after filtration [19]. Deferoxamine
might also enter cells, although this point is controversial.
Deferoxamine conjugated to inulin has an effective molecular
radius of about 14 angstroms. When infused it would have
access to the blood and would then appear in the urinary space
after filtration [20]. Inulin-conjugated deferoxamine would be
excluded from intact cells. Deferoxamine conjugated to dextran
has an effective molecular radius of approximately 42 ang-
stroms and would be essentially excluded from glomerular
filtration [20] and from cells and would, therefore, have access
only to the blood space. Even following ischemia the fractional
excretion of dextran-conjugated deferoxamine would not rise
substantially to deliver deferoxamine to the urinary space [21].
Deferoxamine was infused in a dose of 50 mg/kg/hr for the
first hour of reperfusion. Inulin-conjugated deferoxamine was
infused to provide an equivalent amount of deferoxamine. A
control group of animals received an equivalent amount of
inulin. Dextran-conjugated deferoxamine was given in an amount
(230 mg/kg/hr) to yield plasma concentrations during the first
hour of reperfusion which would approximate those attained
during infusion of a high dose of free deferoxamine of 200
mg/kg/hr. An additional control group received a dextran infu-
sion during the first hour of reperfusion.
Plasma deferoxamine was determined by a spectrophotomet-
ric assay for feroxamine after adding saturating quantities of
iron to plasma samples. Two hundred .d of plasma and 300 .d of
10 mM FeSO4 were incubated at 25°C for one hour. Five
hundred d of 20% trichioroacetic acid was added, the precip-
itate removed by centrifugation, and the supernatant mixed
with an equal volume of 1 M sodium acetate (pH 5.5). Absorb-
ance at 429 nm was measured before and after iron addition,
and the deferoxamine concentration was calculated from the
change in feroxamine concentration using a molar extinction
coefficient of 2300. Plasma samples for deferoxamine determi-
nation were obtained 11, 31, and 61 minutes after the start of
infusion of either free deferoxamine or dextran-conjugated
deferoxamine.
Statistical analysis
All data are reported as mean standard error. Most
comparisons were made by Student's t-test for unpaired sam-
ples. Wilcoxon's rank sum test was used for nonparametric data
(effect of ischemia on urinary free iron). To analyze data from
the studies of the effect of deferoxamine on hemodynamics in
normal rats the paired i-test was employed. Analysis of vari-
ance, followed by Tukey's test for intergroup comparisons, was
used to compare the effect of infusion of deferoxamine, iron-
saturated deferoxamine, or dextrose on postischemic GFR, to
compare the effect of infusion of EDTA-FeCI3, EDTA, or
dextrose on postischemic GFR, and to compare renal malondi-
aldehyde content in nonischemic control kidneys to experimen-
tal and control, postischemic kidneys and to compare the
effects of the various deferoxamine compounds.
Results
Effect of removal of endogenous iron
Twenty-four hours after 60 minutes of renal ischemia the
glomerular filtration rate (GFR) in control rats was 314 74
d/min (N = 6). Animals that had received an infusion of
deferoxamine (200 mg/kg/hr) during the first hour of reperfusion
were markedly protected against renal dysfunction. In these
animals inulin clearance was 879 154 sl/min (N = 6; P <
0.025). Iron-saturated deferoxamine-treated rats had a postisch-
emic inulin clearance of 433 85 4u,lJmin (N = 6), a value not
significantly different from dextrose-infused controls and signif-
icantly lower than in deferoxamine-treated animals (P < 0.05).
Deferoxamine also provided protection against postischemic
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Table 1. Effect of deferoxamme (200 mg/kg/hr) on hemodynamic renal function in normal rats
MAP
mm Hg
V GFR RPF RBF
UNaV
mEq/min
UosmV
pDsm/minpJ/min
Baseline 122 7 ll.l 2.9 1110 77 2.8 1.0 5.0 0.7 0.30 0.14 13.0 2.2
Deferoxamine 106 8 13.5 3.1 995 37 2.8 0.6 5.0 1.0 0.30 0.09 12.1 2.9
P <0.05 NS NS NS NS NS NS
Values are mean SE. Abbreviations are: MAP, mean arterial pressure; V, urine flow rate; GFR, glomerular filtration rate; RPF, renal plasma
flow; RBF, renal blood flow; UNaV, urinary sodium excretion rate; U0V, osmolar excretion rate; NS, not significantly different. N = 5.
Baseline lschemia/reflow Ischemia/reflow
no ischemia control DFO
Fig. 1. Effect of deferoxamine (DFO) on lipid peroxidation after renal
ischemia. Numbers in parentheses represent number of animals stud-
ied. NS, not significantly different; MDA, malondialdehyde.
injury when given in a lower dose. In animals given deferox-
amine in a dose of 50 mg/kg during the first hour of reperfusion
GFR 24 hours later was 624 116 p1/mm (N = 6). Control
animals had a GFR of 285 90 p1/mm 24 hours after ischemia
(N = 6; P < 0.05).
Infusion of deferoxamine during reperfusion also reduced
postischemic lipid peroxidation (Fig. 1). As can be seen there
was a significant increase in renal malondialdehyde content
after 60 minutes of ischemia and 15 minutes of reperfusion in
control animals. The infusion of deferoxamine during the 15
minute period of reperfusion prevented the increase in renal
malondialdehyde content.
This beneficial effect of deferoxamine on postischemic renal
function was not likely to be due to a nonspecific effect of the
agent. Normal animals infused with the higher dose of deferox-
amine (200 mg/kg/hr) showed a significant decrease in mean
arterial pressure without any change in urine flow rate, inulin
clearance, renal plasma flow, renal blood flow, or sodium or
osmolar excretion (Table 1).
Effect of increased iron availability
When iron was administered as the EDTA complex the
effects of renal ischemia were exacerbated. Animals infused
with 5% dextrose had a GFR of 292 62 p1/mm (N = 6).
Animals infused with EDTA alone had a GFR of 349 81
4'min (N = 5) 24 hours after ischemia. However, when
EDTA-FeCI3 was infused during the first five minutes of reper-
fusion GFR 24 hours later was only 138 28 p1/mm (N = 5). By
analysis of variance there was no difference between the 5%
dextrose or EDTA animals. Both of these groups had signifi-
cantly higher GFR than EDTA-FeCI3-infused animals (P <
0.05).
The provision of exogenous iron as EDTA-FeCl3 also caused
an increase in lipid peroxidation after ischemia. Renal malon-
dialdehyde content in nonischemic kidneys was 0.476 0.045
nmol/mg prot. In control animals ischemia and 15 minutes of
reperfusion resulted in an increase in renal malondialdehyde to
0.614 0.083 nmol/mg prot (N = 7), although in this particular
experiment the increase did not reach statistical significance
when using multiple-group analysis. Animals which had re-
ceived EDTA-FeCI3 during the first five minutes of reperfusion
had a greater increase in renal MDA to 0.781 0.102 nmol/mg
prot (N = 8; P < 0.05 vs. nonischemic kidneys).
Morphologic studies
Kidneys from both groups of animals showed extensive
injury. However, this injury was less severe in deferoxamine-
treated animals. Casts derived from brush border or sloughed
proximal tubular cells were found obstructing the lumens of
cortical segments in both groups, but casts in the outer medulla
were more frequent in control kidneys and casts in the inner
medulla were seen only in control kidneys. Congestion of vasa
rectae was also more common in control kidneys. Proximal
tubular cells in both groups showed brush border loss and bleb
formation. In deferoxamine-treated kidneys, however, exten-
sive cellular necrosis and sloughing of cells were much less
often seen than in control kidneys (Figs. 2 and 3). Injury was
also less severe in deferoxamine-treated animals when a semi-
quantitative scoring system was used to score coded slides.
Proximal tubules in control kidneys had a mean score of 7.2
0.1, whereas those of deferoxamine-treated kidneys had a mean
score of 6.7 0.1 (P = 0.053) [22]. Therefore, deferoxamine
resulted in only modest histologic protection compared to the
more substantial functional protection.
Effect of ischemia on free iron
Free iron was not detected in either arterial or renal venous
plasma before, during or following ischemia. However, small
amounts of free iron were detectable in the urine before
ischemia. Following ischemia there were dramatic increases in
urinary free iron, increasing by 10- to 20-fold following ischemia
and reperfusion (Table 2).
Nephron site of protection by iron chelators
GFR in the two control groups was similar (inulin: 220 39
p.1/mm, dextran: 247 63 p.1/mm; Fig. 4). Deferoxamine (50
mg/kglhr) was again found to be protective of inulin clearance
(490 102; P < 0.05 vs. dextran or inulin). Inulin-conjugated
deferoxamine was equally protective as free deferoxamine (560
73 p.1/mm). On the other hand, dextran-conjugated deferox-
0.8
0.6
NSH <0.05—ir-—<0.05—--
0.4
0.2
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Fig. 3. Photomicrograph of kidney from a deferoxamine-treated ani-
mal showing less extensive brush border loss, cast formation and cell
necrosis than control kidney (Fig. 2). Magnification '<300.
amine provided no protection (225 60 p1/mm, NS vs. dextran
or inulin; P C 0.05 vs. deferoxamine) despite equivalent plasma
deferoxamine levels. Plasma deferoxamine after infusion of 200
mg/kg/hr (a higher dose than that used to provide protection in
this experiment) was 0.158 0.02 ifiM in three rats sampled at
three time points each. There was no significant variation of
plasma deferoxamine over time. Plasma deferoxamine level in
dextran-conjugated deferoxamine-infused rats (N = 7) was
0.130 0.01 m (not significantly different).
Discussion
Substantial data now exists to suggest that oxygen free
radicals mediate injury following renal ischemia. Inhibitors of
xanthine oxidase to prevent superoxide radical formation [2, 3,
51, superoxide dismutase to remove superoxide radical [2—5]
and numerous scavengers of hydroxyl radical, such as dimethyl-
thiourea, dimethylsulfoxide and glutathione [2, 23, 24], reduce
renal injury following ischemia. Several of these radical scav-
Table 2. Effect of ischemia and reperfusion on urinary free iron
excretion
Urinary free iron
pmol/30 mm
Baseline
before ischemia 138 54
Reperfusion
15—45 mm 1590 776
45—75 mm 1249 506
Values are mean sE. N = 8 (N = 6for second reperfusion period).
a P < 0.05 vs. baseline
b p c 0.08 vs. baseline
E
0
engers have also been shown to limit postischemic lipid peroxi-
dation [2, 3]. Although it is hypothesized that oxygen free
radicals are produced only during the reperfusion of an isehe-
mic organ, evidence for this relationship in vivo is limited. For
example, lipid peroxidation does not appear to occur to any
great extent during isehemia, but occurs promptly during reper-
fusion [2, 3, 25]. Administration of free radical scavengers only
during the reperfusion period has occasionally been demon-
strated to protect against renal injury [5], but in the majority of
studies animals were given free radical scavengers before
ischemia. In the present study all experimental manipulations
were made at the conclusion of a 60 minute period of renal
ischemia and, therefore, affected only reperfusion-associated
events. The findings are consistent with an effect of free radicals
to produce reperfusion-mediated, rather than ischemia-media-
ted, injury.
Because oxygen free radicals, including hydroxyl radical,
produce postischemic renal injury a role of iron to mediate
hydroxyl radical formation and/or lipid peroxidation would not
be surprising. However, there is little data to support such a
relationship in the kidney. In postisehemic injury of the myo-
cardium a role of iron has been suggested by preliminary studies
[261. Furthermore, iron has been demonstrated to participate in
oxidant-mediated injury in other settings [14, 27—301. We found
a prominent role for iron in postischemic injury of the kidney.
Administration of the iron ehelator deferoxamine during the
first hour of reperfusion resulted in improved renal function
(GFR) and renal histologic findings and largely prevented
postischemic lipid peroxidation. In previous studies of postis-
Dextran Dextran- DFO Inulin Inulin
conjugated conjugated
DFO DFO
Fig. 4. Effect of deferoxomine (DFO) compounds on GFR after renal
ischemio. Numbers in parentheses represent number of animals stud-
ied. NS, not significantly different.
'1?_
'A
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Fig.2. Phoio,nicrograph ,if kidney from a conirol animal sho'in
eXiensive -asi formation and patehy necrosis. Magni&ation x3®.
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chemic renal injury there was good correlation between the
GFR at 24 hours and the amount of lipid peroxidation with the
extent of histologic injury and renal tubular dysfunction [2, 23].
This beneficial effect of deferoxamine could not be attributed to
an iron-independent effect since deferoxamine caused a de-
crease in blood pressure (potentially harmful rather than bene-
ficial) and no effect on urine flow rate, GFR, renal blood flow,
sodium or osmolar excretion. Also, iron-saturated deferox-
amine had no protective effect. Conversely, provision of addi-
tional iron in the form of EDTA-FeCl3 at the time of reperfusion
exacerbated the postischemic decline in GFR and lipid peroxi-
dation. We infused EDTA-FeCI3 rather than Fe Cl3 because free
iron is rapidly bound by transferrin and other binding proteins
in the plasma and would not be available to participate in free
radical reactions [18]. EDTA-FeC13 circulates and is filtered by
the kidney. The iron in this complex is bound loosely so that it
can catalyze hydroxyl radical formation [16]. Therefore, during
reperfusion iron exacerbated renal injury and iron chelation
reduced renal injury.
The assay employed to measure lipid peroxidation, the thio-
barbituric acid test, deserves further comment. Lipid peroxida-
tion involves a number of complex reactions which include
initiation steps by free radicals to form lipid hydroperoxides,
propagation reactions, and ultimately termination steps [7, 31].
Many intermediate products are formed, and measurements of
these intermediate products may give important information
about these peroxidation reactions. In the assay for MDA lipid
hydroperoxides which have been formed in vivo are decom-
posed by acid heating in vitro to yield thiobarbituric acid-
reactive substances including MDA [32]. Both in vivo formation
of lipid hydroperoxides and further decomposition in vitro are
iron dependent [32]. Although MDA is formed in vivo, it is also
metabolized and the amounts present in vivo are small [32].
Unfortunately, there is no wholly satisfactory method for
measuring lipid peroxidation in vivo. In the present study we
interpret the results to indicate that provision of iron as EDTA-
FeCl3 resulted in conditions more favorable for the formation of
lipid hydroperoxides and subsequent degradation products.
Conversely, deferoxamine produced conditions less favorable
for formation of lipid hydroperoxides and their degradation
products. It is also important to remember that although lipid
peroxidation is strong evidence that free radicals have been
present, tissue injury can also result from free radical reactions
with proteins, carbohydrates, and DNA. Therefore, assessment
of lipid peroxidation by any method is most useful to indicate
that free radicals have been generated.
The source of the iron which was involved in postischemic
injury and which was bound by deferoxamine is not clear.
Several possibilities exist. Iron in tissues is predominately
stored as ferritin in the form of ferric iron (Fe3). Reduction of
the iron to ferrous iron (Fe2) results in its mobilization [6].
Release of iron from ferritin can be mediated by xanthine
oxidase, primarily via superoxide radical [8—10]. Therefore, the
postischemic production of superoxide radical could result in
the release of free iron from ferritin. The ferritin could be either
cytosolic or lysosomal in origin [33]. We were unable to
demonstrate a postischemic increase in renal venous plasma
free iron. Either no iron was released into the venous circula-
tion or released iron was rapidly bound by proteins and could
not be detected in our assay. On the other hand, we observed a
striking increase in free iron in the urine following ischemia.
Urine, which is for the most part protein-free, would be unable
to bind iron released from renal tubular epithelial cells during
ischemia or reperfusion. Therefore, iron released into the
urinary space might be particularly dangerous in terms of
promoting free radical formation and lipid peroxidation. This
might explain the sensitivity of the kidney, in general, and of the
brush border, in particular, to postischemic injury [34].
When deferoxamine which had access to the urinary space
(free deferoxamine or inulin-conjugated deferoxamine) was
provided during reperfusion protection was seen. Conversely,
dextran-conjugated deferoxamine, which would undergo little
filtration and thus not be present in the urinary space in a
significant concentration during the first critical 20 to 40 minutes
of reperfusion, provided no protection. These findings suggest
that the free iron detectable in the urine was the critical iron
pool in mediating postischemic renal dysfunction and lipid
peroxidation. Because inulin-conjugated deferoxamine was as
protective as free deferoxamine, substantial entry into cells
would not seem necessary. However, since ischemia might
render cells more permeable to larger molecules such as inulin,
we cannot be certain that the only active site of deferoxamine
was the extracellular space. Nevertheless, it is unlikely that
cells with substantial permeability to inulin could retain
intracellular electrolytes to remain viable. Because dextran-
conjugated deferoxamine did not provide protection, a vascular
site of free radical production (such as, endothelial cells) cannot
be the primary site of iron-mediated postischemic injury.
Consistent with the hypothesis that free radicals are gener-
ated in or near the urinary space are previous findings that only
those free radical scavengers which undergo glomerular filtra-
tion and/or tubular secretion (superoxide dismutase, dimethyl-
thiourea, dimethylsulfoxide, glutathione) are protective [2, 23,
24]. Catalase, which is too large to be filtered, was not protec-
tive [2]. These findings do not require that all postischemic free
radical formation occurs in the urinary space. Intracellular
sources of postischemic 02 and H202 are cytoplasmic xan-
thine oxidase and the mitochondrial electron transport chain
[1]. However, if iron which is released gains entry to the urinary
space (as we have demonstrated) then the final step of OH
formation could take place there. Loss of xanthine oxidase into
the urinary space could accentuate this process. Iron might also
be loosely bound to the lipid membrane of the extensive brush
border and thus direct injury to this location. Deferoxamine in
the urinary space could bind this iron and inhibit its harmful
effects.
Although the Haber-Weiss reaction was suggested above to
be the manner whereby free ferrous iron mediates injury, other
recent in vitro data suggests another possible important mech-
anism. Free iron, particularly when there is molar equivalence
of Fe2 and Fe3, can directly initiate lipid peroxidation [11,
12]. Proponents of this mechanism suggest that oxygen free
radicals are most important in reducing Fe3 to Fe2 to attain
the most favorable ratio of the two iron species [11, 12]. These
phenomena are not readily examined in vivo in complex organs.
The present study is consistent with either possibility and,
regardless of the chemical reaction involved, clearly demon-
strates a critical role of iron in mediating postischemic renal
injury.
These observations have a number of important clinical
implications. Deferoxamine has been safely used in man. Intra-
venous infusion of deferoxamine in doses comparable to those
480 Paller and Hedlund: Iron and postischemic renal injury
used in the present study (30 to 50 mg/kg) have been routinely
used for other indications [35, 36]. Therefore, deferoxamine
might be effective in limiting reperfusion injury in man. Exam-
pies which immediately come to mind are revascularization
procedures and organ transplantation where periods of ische-
mia are followed by controlled reperfusion. Iron may also be
responsible for or contribute to hemoglobin- and myoglobin-
induced acute renal failure. Hemoglobin can catalyze the
Haber-Weiss reaction in vitro [37]. If iron from methemoglobin
is released as free ferric iron, it too would be amenable to
complexation by deferoxamine. In this setting deferoxamine
would limit any additional iron-promoted injury. Studies from
our laboratory suggest that this is indeed the case [38].
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